e8vk
 

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report
(Date of earliest event reported): March 17, 2005

Zonagen, Inc.

(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction of
incorporation or organization) 		  0-21198
(Commission File Number) 		  76-0233274
(I.R.S. Employer Identification No.)

2408 Timberloch Place, Suite B-1
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant’s telephone
number, including area code)

 
 

 

 

Item 8.01. Other Information

     Zonagen, Inc. announced in a press release on March 17, 2005 that, on March 2, 2005, the United States Patent and Trademark Office issued U.S. Pat. No. 6,861,415 which claims both compositions of matter and methods of use for Progenta™, which Zonagen is currently developing for the treatment of uterine fibroids and endometriosis. Zonagen is the exclusive worldwide licensee of this patent.

     A copy of the Company’s press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

Item 9.01. Financial Statements and Exhibits

     c. Exhibits

     
Exhibit    
Number   Description
   99.1
  Press Release dated March 17, 2005.

 

 

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
  Zonagen, Inc.
 		  
Date: March 18, 2005.  By:   /s/ Louis Ploth, Jr.    
    Louis Ploth, Jr.   
    Vice President, Business Development and Chief Financial Officer   
 

 

 

EXHIBIT INDEX

     
Exhibit    
Number   Description
   99.1
  Press Release dated March 17, 2005.